Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Veeva Systems Inc. VEEV

Healthcare — Health Information Services
S&P 500 Member Cash Flow Champion (10y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
21.38
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 4 — — 1 — 1 2 — — 1 2 2
Insider Ownership
9.08%

Capital & Financial Ratios

Market Cap
42,830.00
Revenue
3,458.10
Net Income
1,014.77
Free Cash Flow
1,638.77
Net Debt
(7,242.95)
Current Ratio
5.46
Debt/Equity
0.00
P/E ratio
42.47
P/S ratio
12.38
P/B ratio
5.76
Past 5Y EPS Growth
17.84%
This Y EPS Growth
14.01%
Next Y EPS Growth
11.19%
Next 5Y EPS Growth
12.51%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2027 ‡‡‡‡‡
2026 ‡‡‡‡‡
2025 ‡‡‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 4,027.76 5,150.23 6,560.81 7,242.95
Receivables 888.54 1,057.12 1,310.35 565.65
Inventory — — — —
Other 86.92 101.46 — —
5,003.21 6,308.80 7,997.63 7,946.23
2024 2025 2026 Q'26
Payables 31.51 30.45 37.64 35.98
ST’ Debt — — — —
Other — — — —
1,178.88 1,398.40 1,637.06 1,455.95
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Apr Jul Oct Jan Year
’26 882.95 927.96 — —
—
’26 759.04 789.08 811.24 835.95
3,195.31
’25 650.35 676.18 699.21 720.89
2,746.62
’24 526.33 590.23 616.51 630.62
2,363.67
’23 505.10 534.22 552.35 563.39
2,155.06
’22 433.57 455.59 476.11 485.50
1,850.78
’21 337.11 353.68 377.52 396.76
1,465.07
in millions of $

Operating Cash Flow

Apr Jul Oct Jan Year
’26 1,127.12 238.71 — —
—
’26 877.16 238.43 192.79 106.85
1,415.23
’25 763.52 92.87 164.12 69.54
1,090.05
’24 505.94 265.04 82.60 57.77
911.34
’23 481.03 93.39 142.66 63.40
780.47
’22 478.39 119.07 112.96 54.05
764.46
’21 282.17 105.32 95.40 68.35
551.25
in millions of $

Free Cash Flow

Apr Jul Oct Jan Year
’26 1,125.37 230.69 — —
—
’26 871.25 232.13 182.90 99.82
1,386.09
’25 755.04 89.82 159.85 64.82
1,069.53
’24 502.98 255.44 76.69 50.03
885.14
’23 478.69 91.72 137.05 59.49
766.96
’22 475.73 113.74 110.65 50.14
750.25
’21 282.44 99.91 92.09 68.12
542.56
in millions of $

EPS

Apr Jul Oct Jan Year
’26 1.57 1.66 — —
—
’26 1.37 1.19 1.40 1.45
5.44
’25 0.98 1.04 1.13 1.18
4.32
’24 0.81 0.68 0.83 0.90
3.22
’23 0.62 0.56 0.67 1.16
3.00
’22 0.71 0.67 0.65 0.60
2.63
’21 0.54 0.58 0.60 0.64
2.36

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.8
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 151.02 157.00 170.25 201.54 148.05 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 257.68 225.49 258.93 310.50 296.24 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,482 6,744 7,172 7,291 7,928 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.34 0.32 0.33 0.38 0.40 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,850.78 2,155.06 2,363.67 2,746.62 3,195.31 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 72.79% 71.72% 71.35% 74.53% 75.53% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 512.31 509.10 588.02 919.38 1,194.51 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.68% 23.62% 24.88% 33.47% 37.38% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 427.39 487.71 525.71 714.14 908.91 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 59.76 47.59 24.29 30.47 44.70 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.08 13.87 14.72 16.97 19.52 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 2.79 3.14 3.27 4.41 5.55 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.99 5.02 5.68 6.73 8.65 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.09) (0.09) (0.16) (0.13) (0.18) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.90 4.94 5.51 6.61 8.47 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.00 23.92 28.93 36.03 44.08 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 153.25 155.39 160.53 161.88 163.67 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 84.78 54.49 63.23 52.89 36.57 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.59 12.30 14.09 13.75 10.42 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.45 7.13 7.17 6.47 4.61 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.33 10.89 12.41 11.89 8.38 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 45.22 30.59 33.13 30.54 19.32 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 764.46 780.47 911.34 1,090.05 1,415.23 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.21) (13.51) (26.20) (20.52) (29.13) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 750.25 766.96 885.14 1,069.53 1,386.09 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,266.40 2,962.51 3,824.33 4,910.40 6,360.57 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ 55.00 61.00 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2,321.10) (3,041.63) (4,027.76) (5,150.23) (6,560.81) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,911.64 3,716.25 4,644.82 5,832.37 7,214.75 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.46% 11.31% 9.81% 10.78% 11.14% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 53.50% 42.53% 43.49% 63.35% 87.58% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.51% 14.72% 12.58% 13.63% 13.93% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Veeva Systems (VEEV), a cloud software powerhouse for life sciences, has delivered impressive growth with revenue surging at a 28% CAGR from 2016 to 2023, reaching $2.75 billion in 2024, fueled by CRM, Vault, and regulatory tools amid pharma’s digital shift. A pristine balance sheet—boasting $5.15 billion in net cash and ROIC at 43%—underpins steady profitability, with EPS climbing 698% over the decade and free cash flow per share hitting $5.51. Yet, as growth moderates to 12-15% through 2027 and gross margins stabilize near 75%, the stock trades at elevated 33x forward EV/FCF, sensitive to macro headwinds and post-pandemic normalization.

Analyst targets signal strong upside—84% on average, up to 118%—betting on AI integrations, international expansion, and cross-selling to top pharma clients. Operational efficiency shines through revenue per employee rebounding to $377,000 and minimal capex, positioning Veeva as a quality compounder. However, red flags like $9.85 million in insider selling with zero buys raise eyebrows, echoing 2022’s 30% drawdown amid competition from Salesforce and Medidata.

This resilient performer merits a hold for conservative portfolios, but flawless execution is key amid risks of R&D budget scrutiny and inefficient cash deployment. Dive into the full analysis for the data-driven narrative on whether Veeva’s fortress holds or cracks under normalizing growth.

Read full commentary →

Veeva Systems Inc. (VEEV) Latest News

News by impact score

Fine-tune

15 Sep

3 , 7:03 AM
Leading biotech selects Veeva Vault CRM globally. Single client win adds revenue but does not shift overall trajectory.

14 Sep

4 www.marketbeat.com, 2:02 AM
Veeva Systems positions artificial intelligence as a primary growth driver expected to exceed the company's $6 billion revenue goal by 2030. AI strategy drives accelerated revenue growth past 2030 targets and strengthens competitive positioning.

4 www.marketbeat.com, 1:02 AM
Veeva Systems launches Falcon AI product as its commercial growth accelerates. Falcon AI introduction represents major product launch that can significantly shift Veeva competitive positioning and growth trajectory.

4 Sep

4 , 12:38 AM
Veeva Systems leads in AI applications for biopharma via specialized platforms, partnerships and market positioning that strengthen its competitive edge. Veeva's AI advancements in biopharma signal major strategic gains likely to boost long-term performance and investor outlook.

3 Sep

4 , 2:10 PM
Veeva Systems raised its FY27 outlook due to accelerating momentum in Vault CRM and AI initiatives. Raised FY27 outlook combined with Vault CRM and AI acceleration signals major positive shifts in growth trajectory and investor sentiment.

1 Sep

3 , 7:03 AM
Veeva Falcon Safety integrates with all E2B-compliant safety systems across any intake channels. Compatibility expansion broadens Veeva safety offerings and may lift adoption in regulated markets but stops short of major strategic or financial shifts.

31 Aug

3 transcript www.fool.com, 9:49 AM
Veeva Systems Inc. (VEEV) released its Q2 2027 earnings call transcript detailing quarterly financial results and business updates. Quarterly earnings disclosures typically affect short-term stock sentiment and valuation without guaranteed long-term strategic shifts.

28 Aug

4 www.fool.com, 6:16 AM
Veeva Systems stock surges this week on positive developments driving investor interest and share price gains. Stock surge signals major positive events likely to alter company trajectory and sentiment.

3 , 10:43 PM
Veeva Systems achieved 16% subscription revenue growth alongside 40% GAAP operating income increase, with questions on sustainability of margin expansion. Revenue and operating income gains signal moderate financial progress but sustainability doubts prevent fundamental trajectory shifts.

27 Aug

4 , 9:13 PM
Veeva Systems expands AI capabilities, secures CRM wins, and accelerates R&D Cloud adoption in Q2. AI expansion combined with CRM wins and faster R&D Cloud adoption signals major strategic advances that can shift competitive positioning and investor outlook.

4 transcript , 10:37 AM
Veeva Systems Q2 earnings call highlighted Falcon and CRM momentum. Earnings focus on Falcon and CRM signals major product momentum that can shift company trajectory.

4 transcript app.moby.co, 8:30 AM
Veeva Systems Inc. held its Q2 2027 earnings call covering revenue, growth metrics, product updates, and forward guidance. Q2 2027 earnings results and guidance directly shape investor views and near-term stock trajectory for Veeva.

4 , 1:01 AM
Veeva Systems posted record CRM results in Q2 2027 with accelerating AI adoption supporting continued expansion in life sciences software. Record CRM performance and AI momentum indicate major positive effects on Veeva revenue trajectory and competitive standing.

3 , 10:19 PM
Veeva Systems earnings beat expectations and returns focus to its valuation. Earnings beat can influence short-term market sentiment and investor focus on valuation metrics.

3 , 3:09 PM
Truist Securities states Veeva Systems is executing successfully across CRM, AI, and Commercial Cloud. Positive analyst note on execution in core areas may moderately lift market sentiment and stock trajectory.

3 www.fool.com, 2:07 PM
Veeva Systems Inc. shares rose sharply today after company developments lifted investor sentiment and drove buying activity. Stock surge reflects moderately positive developments that may support near-term sentiment without fundamentally reshaping long-term trajectory.

3 , 11:31 AM
Veeva Systems Inc. exceeded Q2 earnings and revenue estimates, resulting in an increase in its stock price. Q2 earnings beat provides moderate short-term boost to stock performance without signaling major strategic or competitive shifts.

26 Aug

4 , 5:00 PM
Veeva Systems Inc. exceeded Q2 CY2026 sales estimates, driving a sharp surge in its stock price. Beating quarterly sales estimates typically drives immediate stock gains and shifts investor outlook for Veeva Systems.

4 , 4:05 PM
Veeva Systems Inc. (VEEV) announced its fiscal 2027 second quarter results. Quarterly earnings directly affect investor sentiment and near-term stock trajectory for Veeva.

3 transcript www.marketbeat.com, 7:04 PM
Veeva Systems held its Q2 earnings call, covering financial results, guidance, and operational updates. Q2 earnings call delivers financial metrics and guidance that can shift short-term investor sentiment.

3 , 6:00 PM
Veeva Systems reported Q2 results with key metrics showing subscription revenue trends, customer additions, and operating margins that shape views on its life sciences software performance. Q2 earnings metrics offer moderate signals on revenue growth and margins that can influence near-term investor views without major strategic changes.

3 , 5:20 PM
Veeva Systems Inc. reported Q2 earnings and revenues exceeding analyst estimates. Beating quarterly earnings and revenue estimates can produce a moderate positive effect on near-term stock performance and sentiment.

25 Aug

3 , 2:59 PM
Veeva Systems' Vault CRM wins reinforce its market-leader status ahead of earnings, according to Truist. Vault CRM wins strengthen Veeva's competitive position and may enhance investor confidence ahead of earnings.

3 , 7:03 AM
Biogen selects Veeva Vault CRM. Biogen selection of Veeva Vault CRM adds a major life sciences client and supports revenue growth without altering company trajectory.

3 , 7:03 AM
Regeneron selects Veeva Vault CRM. Regeneron adoption expands Veeva customer base in life sciences.

24 Aug

3 , 12:32 PM
Veeva Systems may see Q2 results boosted by AI innovations and CRM wins. AI and CRM developments could moderately influence Veeva financial performance and positioning.

22 Aug

4 , 4:08 AM
Eli Lilly signed a global Vault CRM deal with Veeva Systems amid a leadership shift at Veeva, prompting questions on whether these events will alter the company's market narrative. Eli Lilly global Vault CRM contract marks a major client expansion that can materially lift Veeva revenue and competitive standing.

14 Aug

3 , 9:28 PM
Veeva Systems Inc. (VEEV) questions whether its AI platform can match Eli Lilly and Company (LLY)'s explosive growth. Veeva faces potential pressure on its AI capabilities relative to a major pharma client's rapid expansion.

11 Aug

4 , 7:03 AM
Veeva Vault CRM selected by Eli Lilly and Company. Eli Lilly adoption of Vault CRM adds major customer revenue and strengthens Veeva competitive position.

10 Aug

3 , 5:09 PM
Veeva Systems (VEEV) executed a latest move whose underlying drivers and implications are under review. Latest move may moderately affect operations or positioning but lacks detail on scale.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us